{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=35",
    "query": {
      "intervention": "Phase 1b",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 2481,
    "total_pages": 249,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T11:32:52.961Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06765980",
      "title": "A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy Secondary to Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "VV-14295",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Kriya Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 62,
      "start_date": "2025-05-28",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 1,
      "location_summary": "Erie, Pennsylvania",
      "locations": [
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06765980"
    },
    {
      "nct_id": "NCT02474173",
      "title": "Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Onalespib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2016-01-15",
      "completion_date": "2022-10-26",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 4,
      "location_summary": "Lexington, Kentucky • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02474173"
    },
    {
      "nct_id": "NCT07187973",
      "title": "A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "DISC-3405",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Disc Medicine, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-01-06",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07187973"
    },
    {
      "nct_id": "NCT05320146",
      "title": "A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "MRI-PDFF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 22,
      "start_date": "2022-03-04",
      "completion_date": "2023-07-18",
      "has_results": false,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 9,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05320146"
    },
    {
      "nct_id": "NCT03955939",
      "title": "A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LY3295668 Erbumine",
          "type": "DRUG"
        },
        {
          "name": "Endocrine therapy",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2019-08-02",
      "completion_date": "2020-05-14",
      "has_results": false,
      "last_update_posted_date": "2020-06-01",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Boston, Massachusetts • San Antonio, Texas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03955939"
    },
    {
      "nct_id": "NCT04458545",
      "title": "Clinical Trials of Multivalent Opioid Vaccine Components",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Opioid-use Disorder"
      ],
      "interventions": [
        {
          "name": "Oxy(Gly)4-sKLH vaccine - Low Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oxy(Gly)4-sKLH vaccine - High Dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Oxy(Gly)4-sKLH vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 45,
      "start_date": "2020-10-08",
      "completion_date": "2027-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 2,
      "location_summary": "Eatontown, New Jersey • New York, New York",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04458545"
    },
    {
      "nct_id": "NCT07780565",
      "title": "Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Monzosertib",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole",
          "type": "DRUG"
        },
        {
          "name": "Isavuconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2027-01-01",
      "completion_date": "2031-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07780565"
    },
    {
      "nct_id": "NCT04641871",
      "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Sym021",
          "type": "DRUG"
        },
        {
          "name": "Sym022",
          "type": "DRUG"
        },
        {
          "name": "Sym023",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Symphogen A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2020-10-12",
      "completion_date": "2024-06-03",
      "has_results": false,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04641871"
    },
    {
      "nct_id": "NCT03412799",
      "title": "Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer Metastatic",
        "Pancreatic Cancer Stage IV",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "SBP-101",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Panbela Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-06-04",
      "completion_date": "2022-02-28",
      "has_results": false,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Gainesville, Florida • Rochester, New York",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03412799"
    },
    {
      "nct_id": "NCT02576665",
      "title": "A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "Pancreatic Cancer",
        "Non-Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Ovarian Cancer",
        "Lymphoma",
        "Sarcoma",
        "Bladder Cancer",
        "Melanoma",
        "IDH1 Mutated Solid Tumors",
        "IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)"
      ],
      "interventions": [
        {
          "name": "Toca 511",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Toca FC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Tocagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2016-07",
      "completion_date": "2019-12-20",
      "has_results": false,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-10-21T11:32:52.961Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Miami, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576665"
    }
  ]
}